LISATA THERAPEUTICS INC (LSTA)
US1280583022 - Common Stock
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon and appendiceal cancers
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon and appendiceal...
Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging
License provides Lisata’s innovative certepetide targeting agent for use with Kuva’s NanoMark™ MR imaging platform to advance non-invasive, high-precision cancer diagnostics
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
Award recognizes Lisata’s data-driven approach and innovative therapies designed to address the unmet medical needs of patients with advanced solid tumors ...
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30...
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
Study will investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in preclinical tumor models
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
Study will investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's platform technology, PeptiCRAd, and a...
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
BASKING RIDGE, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing...
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
BASKING RIDGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing...
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
Strategic partnership explores therapeutic effect of Lisata’s novel cyclic peptide product candidate, certepetide, in combination with bevacizumab
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
Strategic partnership explores therapeutic effect of Lisata’s novel cyclic peptide product candidate, certepetide, in combination with bevacizumab...
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
Study arm initiated based upon enthusiasm and at the request of investigators who participated in first-line cholangiocarcinoma cohort
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
BASKING RIDGE, N.J. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
BASKING RIDGE, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q2 2024
LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lisata Therapeutics (NASDAQ:LSTA) just reported results for the second quarter ...
Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Phase 2b ASCEND trial top-line data remains on track to be reported in fourth quarter of 2024 Available cash projected to fund current operations into...
Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
BASKING RIDGE, N.J., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
BALTIMORE, Md. and BASKING RIDGE, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, and Lisata...
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
Complete enrollment achieved nearly six months ahead of plan Top-line data now anticipated mid-2025 Addition of second-line cholangiocarcinoma arm to...
Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
Certepetide shown to promote immune cell infiltration into tumors and inhibit metastasis
Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
Certepetide shown to promote immune cell infiltration into tumors and inhibit metastasis...
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and appendiceal...
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
BASKING RIDGE, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...